{"id":"W2982284711","doi":"10.1007/s11136-019-02296-5","title":"Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis","year":2019,"lang":"en","type":"article","venue":"Quality of Life Research","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research; Dalhousie University","funders":"Eli Lilly and Company","keywords":"Ixekizumab; Medicine; Placebo; Psoriasis; Quality of life (healthcare); Internal medicine; Randomized controlled trial; Physical therapy; Clinical trial; Psoriatic arthritis; Immunology; Secukinumab; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003851527,0.001621125,0.004415447,0.0003839459,0.0004569697,0.001726026,0.000931053,0.001725707,0.002429746],"category_scores_gemma":[0.003728189,0.0006076706,0.005146376,0.0008240588,0.001525059,0.0009357664,0.0005735767,0.003572941,0.0002539256],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009411895,"about_ca_system_score_gemma":0.0009282518,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001668915,"about_ca_topic_score_gemma":0.002250398,"domain_scores_codex":[0.9982805,0.000928328,0.0001709086,0.0002342754,0.0001588952,0.0002271437],"domain_scores_gemma":[0.9970534,0.001356142,0.0008421326,0.0001754174,0.0001256241,0.0004473475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.966827,0.002042205,0.002985676,0.001781942,0.006693014,0.00003578621,0.00006832006,0.0005498637,0.001575182,0.00008138984,0.0005803438,0.01677929],"study_design_scores_gemma":[0.9333249,0.0443924,0.01448576,0.0001531481,0.006072136,0.00006291572,0.00006484135,0.0002989805,0.000333738,0.0001649421,0.0006110176,0.00003521758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.949498,0.0455377,0.0005144703,0.001037438,0.000488178,0.0008512031,0.001025663,0.00004958744,0.0009976521],"genre_scores_gemma":[0.9853403,0.01049246,0.0008357087,0.0007463758,0.0003657859,0.000723007,0.0009729509,0.00001715967,0.0005062605],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004415447,"threshold_uncertainty_score":0.02036911,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1178813472770215,"score_gpt":0.3865356601332807,"score_spread":0.2686543128562591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}